QUTENZA
Peakcapsaicin
NDATOPICALPATCH
Approved
Nov 2009
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
20
Data completeness
4/8 — Partial
Drug data last refreshed 13h ago · AI intelligence enriched 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
QUTENZA is a topical capsaicin patch approved for neuropathic pain relief, delivering high-concentration capsaicin directly to affected skin areas. Capsaicin works by desensitizing nociceptors and reducing substance P, a pain neurotransmitter, providing localized analgesia without systemic absorption. It is indicated for postherpetic neuralgia and other peripheral neuropathic pain conditions.
$12MPart D
PeakStable
3.5 years to LOEProduct is at peak lifecycle with modest Part D uptake of 3,559 claims; commercial team is stable and focused on maintaining market position against strong competitive pressure.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Alcohol Neurolysis and Capsaicin for Postamputation Pain (PAP)
Started Oct 2026
120 enrolled
Postamputation Pain
A Study of BL1332 on Capsaicin-Induced Ocular Pain in Healthy Trial Participants
Started Jul 2026
28 enrolled
Healthy
Study to Investigate the Pharmacodynamic Effects of IP2015 in Healthy Male Subjects Using the Intradermal Capsaicin Model
Started Jan 2022
24 enrolled
Pain
Preliminary Study of CA-008 (Vocacapsaicin) in Patients Undergoing Ventral Hernia Repair
Started Sep 2020
34 enrolled
Postsurgical Pain
Study Evaluating the Safety, Efficacy and Pharmacokinetics of CA-008 (Vocacapsaicin)
Started Dec 2019
193 enrolled
Postsurgical Pain
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.